Kyowa Hakko Kirin

Ardelyx, Inc. Reports Employment Inducement Grants

Retrieved on: 
Wednesday, November 2, 2022
Metabolic acidosis, Adult, Nasdaq, Dialysis, Employment, View, Indian stock exchange, Hyperkalemia, Fosun Pharma, RSU, Therapy, CKD, Kyowa Hakko Kirin, Patient, Kidney, Multimedia, Knight Therapeutics, Health insurance, Pharmaceutical industry

The stock options and RSUs were granted as inducements material to each employee's decision to enter into employment with Ardelyx, in accordance with Nasdaq Listing Rule 5635(c)(4).

Key Points: 
  • The stock options and RSUs were granted as inducements material to each employee's decision to enter into employment with Ardelyx, in accordance with Nasdaq Listing Rule 5635(c)(4).
  • Each stock option vests over four years, with 25% of the shares vesting on the first anniversary of the employee's first date of employment, and the remaining 75% of shares vesting monthly thereafter.
  • Each stock option has a 10-year term, and each option and RSU is subject to the terms and conditions of the company's 2016 Employment Commencement Incentive Plan and the award agreement covering the grant.
  • Ardelyx was founded with a mission to discover, develop and commercialize innovative first-in-class medicines that meet significant unmet medical needs.

Kyowa Hakko USA Highlights Branded Ingredients and New Innovations at SupplySide West 2022

Retrieved on: 
Tuesday, November 1, 2022
Marketing, MD, Food and Drug Administration, McGlade, MBA, Supplier, Kyowa Hakko Kirin, GRAS, PDC, Disease, Immune system, Interview, Memory, Fermentation, South by Southwest, Video, Food, NK, RD, Adolescence, Attention, Pharmaceutical industry, Vaccine, Dietary supplement, Citicoline

NEW YORK, Nov. 1, 2022 /PRNewswire-PRWeb/ -- Kyowa Hakko USA, leading international health ingredient manufacturer and world leader in the development, manufacturing, and marketing of pharmaceuticals, nutraceuticals and food products, announces featured events for IMMUSE™ a postbiotic that delivers a new, breakthrough approach to more comprehensive immune support* and Cognizin® Citicoline, a clinically studied and branded form of Citicoline.

Key Points: 
  • Following the presentation, Dr. Moday will be at the Kyowa Hakko Booth # 3065 starting at 1:00 pm to sign her recent book, The Immunotype Breakthrough.
  • Its unique mechanism of action, discovered by Kyowa Hakko's parent company Kirin Holdings Co., Ltd., is opening doors for discovering postbiotics concerning immune health.
  • So, we decided to make it available to everyone interested in powering their game," commented Karen Todd, MBA, RD, Vice President Global Brand Marketing, Kyowa Hakko USA, Inc.
  • Kyowa Hakko USA is the North & South American office for Kyowa Hakko Bio Co. Ltd., an international health ingredients manufacturer and world leader in the development,
    Media interested in setting up an interview with Heather Moday MD, or Karen Todd, please drop by the Kyowa Hakko booth # 3065 or call Sue Taggart at 917.833.8101.

Ardelyx to Report Third Quarter 2022 Financial Results on November 3, 2022

Retrieved on: 
Thursday, October 27, 2022
Kyowa Hakko Kirin, Review, Kidney, Investor, Dialysis, Webcast, Therapy, Patient, Hyperkalemia, Nasdaq, Conference, Multimedia, Metabolic acidosis, CKD, View, Knight Therapeutics, Conference call, Adult, Fosun Pharma, Pharmaceutical industry

WALTHAM, Mass., Oct. 27, 2022 /PRNewswire/ -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative first-in-class medicines that meet significant unmet medical needs, today announced that it will hold a conference call on Thursday, November 3, 2022, at 4:30 p.m. Eastern Time to review third quarter 2022 financial results and provide a business overview.

Key Points: 
  • To participate in the conference call, please dial (866) 374-5140 (domestic) or (404) 400-0571 (international) and enter the pin 79680409#.
  • Ardelyx was founded with a mission to discover, develop and commercialize innovative first-in-class medicines that meet significant unmet medical needs.
  • Ardelyx is developing XPHOZAH (tenapanor), a novel product candidate to control serum phosphorus in adult patients with CKD on dialysis, which has completed three successful Phase 3 trials.
  • Ardelyx has established agreements with Kyowa Kirin in Japan, Fosun Pharma in China and Knight Therapeutics in Canada for the development and commercialization of tenapanor in their respective territories.

Ardelyx Announces Poster Presentations on XPHOZAH® (tenapanor) at ASN's Kidney Week 2022

Retrieved on: 
Thursday, October 20, 2022
PAI, ASN, ESRD, Dialysis, Therapy, Patient, Diarrhea, NHE3, Multimedia, Knight Therapeutics, Fosun Pharma, Kidney, Kyowa Hakko Kirin, Metabolic acidosis, MD, Hyperphosphatemia, Blood, Phosphorus, Adult, Hyperkalemia, CKD, View, Pharmaceutical industry

In addition to the poster presentations during ASN, Ardelyx is sponsoring an Exhibitor Spotlight titled: The Phosphorus Management Puzzle and Need for New Pieces: the Patient and Physician Perspective, on Saturday November 5, 2022, from 12:30-1:15pm ET.

Key Points: 
  • In addition to the poster presentations during ASN, Ardelyx is sponsoring an Exhibitor Spotlight titled: The Phosphorus Management Puzzle and Need for New Pieces: the Patient and Physician Perspective, on Saturday November 5, 2022, from 12:30-1:15pm ET.
  • XPHOZAH (tenapanor), discovered and developed byArdelyx, is an investigational first-in-class phosphate absorption inhibitor (PAI).
  • The kidney is the organ responsible for regulating phosphorus levels, but when kidney function is significantly impaired, phosphorus is not adequately eliminated from the body.
  • Ardelyx is developing XPHOZAH (tenapanor), a novel product candidate to control serum phosphorus in adult patients with CKD on dialysis, which has completed three successful Phase 3 trials.

Synaffix Licenses CliCr® Chemistry from Cristal Therapeutics to Fortify Best-in-Class ADC Technology Offering

Retrieved on: 
Tuesday, October 18, 2022
Therapy, Therapeutic index, Biotechnology, Technology, Kyowa Hakko Kirin, Alfred Noble Prize, Cristal, COGS, Aravis, Fluorophore, ADC, Moa, Nanoparticle, Emergence, Click chemistry, Peptide, Control, Nucleotide, Fine chemical, Pharmaceutical industry, Chemistry, Synaffix

Under the terms of the agreement, Synaffix will obtain exclusive rights to theCliCr technology, to combine with its proprietary ADC platform technology.

Key Points: 
  • Under the terms of the agreement, Synaffix will obtain exclusive rights to theCliCr technology, to combine with its proprietary ADC platform technology.
  • Floris van Delft, Chief Scientific Officer of Synaffix, said:"We areimpressedby the properties ofCliCr,which clearly demonstrate best-in-class potential as chemistry formetal-free clickconjugationwith azides.
  • Cristianne Rijcken, Chief Scientific Officer of Cristal Therapeutics stated: "We are emboldened by this license agreement with Synaffix, a leading provider of ADC technology, as it underscores the potential of our unique CliCr technology.
  • The business model of Synaffix is target-specific technology out-licensing, as exemplified through its existing deals with ADC Therapeutics, Mersana Therapeutics, Shanghai Miracogen, Innovent Biologics, ProfoundBio, Kyowa Kirin, Genmab, Macrogenics and Emergence Therapeutics.

Synaffix Licenses CliCr® Chemistry from Cristal Therapeutics to Fortify Best-in-Class ADC Technology Offering

Retrieved on: 
Tuesday, October 18, 2022
Therapy, Therapeutic index, Biotechnology, Technology, Kyowa Hakko Kirin, Alfred Noble Prize, Cristal, COGS, Aravis, Fluorophore, ADC, Moa, Nanoparticle, Emergence, Click chemistry, Peptide, Control, Nucleotide, Fine chemical, Pharmaceutical industry, Chemistry, Synaffix

Under the terms of the agreement, Synaffix will obtain exclusive rights to theCliCr technology, to combine with its proprietary ADC platform technology.

Key Points: 
  • Under the terms of the agreement, Synaffix will obtain exclusive rights to theCliCr technology, to combine with its proprietary ADC platform technology.
  • Floris van Delft, Chief Scientific Officer of Synaffix, said:"We areimpressedby the properties ofCliCr,which clearly demonstrate best-in-class potential as chemistry formetal-free clickconjugationwith azides.
  • Cristianne Rijcken, Chief Scientific Officer of Cristal Therapeutics stated: "We are emboldened by this license agreement with Synaffix, a leading provider of ADC technology, as it underscores the potential of our unique CliCr technology.
  • The business model of Synaffix is target-specific technology out-licensing, as exemplified through its existing deals with ADC Therapeutics, Mersana Therapeutics, Shanghai Miracogen, Innovent Biologics, ProfoundBio, Kyowa Kirin, Genmab, Macrogenics and Emergence Therapeutics.

TransPerfect Life Sciences Hosts “Conversations on Clinical Content” Event Series

Retrieved on: 
Thursday, October 13, 2022
Health, Technology, Software, Clinical Trials, Pharmaceutical, Biotechnology, PPD, ISO, COA, AstraZeneca, TransPerfect, ProofPilot, City, Roche, C3, Decentralized Trials & Research Alliance, Technology, Pharmacovigilance, Kyowa Hakko Kirin, DCT, Clinical data management, Industry, Boehringer Ingelheim, TMF, Red nucleus, Bristol Myers Squibb, DCTS, MANA, Solution, Language, Fine chemical, Pharmaceutical industry, Management, Walgreens, Pfizer, Exponentiation, Parexel

TransPerfect Life Sciences , a leading provider of services and technologies to support global clinical trials and product development for the biopharmaceutical industry, today announced a final call for registration for the 2022 Conversations on Clinical Content (C3) summit.

Key Points: 
  • TransPerfect Life Sciences , a leading provider of services and technologies to support global clinical trials and product development for the biopharmaceutical industry, today announced a final call for registration for the 2022 Conversations on Clinical Content (C3) summit.
  • The event is the third in a three-part series and takes place on October 20 in Princeton, NJ.
  • C3 brings together leading industry executives with expertise in product development and decentralized clinical trials (DCTs) for regional meetings and virtual sessions.
  • TransPerfect Life Sciences specializes in supporting global development and commercialization of drugs, treatments, and devices designed to improve and save lives.

TransPerfect Life Sciences Hosts "Conversations on Clinical Content" Event Series

Retrieved on: 
Thursday, October 13, 2022
PPD, ISO, COA, AstraZeneca, TransPerfect, ProofPilot, City, Solution, Roche, C3, Decentralized Trials & Research Alliance, Multimedia, Technology, Pharmacovigilance, Kyowa Hakko Kirin, DCT, Clinical data management, Industry, Boehringer Ingelheim, TMF, Red nucleus, Bristol Myers Squibb, DCTS, MANA, Language, Fine chemical, Pharmaceutical industry, Management, Online shopping, Walgreens, Pfizer, Exponentiation, Parexel

NEW YORK, Oct. 13, 2022 /PRNewswire/ -- TransPerfect Life Sciences, a leading provider of services and technologies to support global clinical trials and product development for the biopharmaceutical industry, today announced a final call for registration for the 2022 Conversations on Clinical Content (C3) summit. The event is the third in a three-part series and takes place on October 20 in Princeton, NJ. Registration and details can be found at https://thec3summit.com/princeton/.

Key Points: 
  • The event is the third in a three-part series and takes place on October 20 in Princeton, NJ.
  • C3 brings together leading industry executives with expertise in product development and decentralized clinical trials (DCTs) for regional meetings and virtual sessions.
  • As an audience member, the event served as an effective forum to demystify a number of topics related to patient centricity."
  • TransPerfect Life Sciences specializes in supporting global development and commercialization of drugs, treatments, and devices designed to improve and save lives.

U.S. Patent & Trademark Office Allows AVEO Oncology’s Patent Application Covering Use of FOTIVDA® for the Treatment of Refractory Advanced Renal Cell Carcinoma

Retrieved on: 
Wednesday, October 12, 2022
Approved Drug Products with Therapeutic Equivalence Evaluations, Renal cell carcinoma, Disease, SEC, ZS Associates, Population, Woman, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Patient, Result, Kidney cancer, Man, Jazz Pharmaceuticals, Financial condition report, ZS, Nasdaq, Private Securities Litigation Reform Act, RCC, Food, Capital, Kyowa Hakko Kirin, VEGF receptor, Analysis, VEGFR, Industry, United States Patent and Trademark Office, Â, Application, Patent, Adult, Safety, GLOBE, Environment, USPTO, European, Intellectual property, American Cancer Society, VEGF, FDA, COVID-19, Half-life, TKI, Pharmaceutical industry, Cancer

A Notice of Allowance is issued after the USPTO decides that a patent can be granted from a patent application.

Key Points: 
  • A Notice of Allowance is issued after the USPTO decides that a patent can be granted from a patent application.
  • The majority of patent applications that receive a Notice of Allowance will issue as a U.S. patent once the issue fee is paid.
  • Food and Drug Administration(FDA) approval for FOTIVDA onMarch 10, 2021for the treatment of adult patients with relapsed or refractory advanced renal cell carcinoma (RCC) following two or more prior systemic therapies.
  • AVEO currently markets FOTIVDA (tivozanib) in theU.S.for the treatment of adult patients with relapsed or refractory advanced renal cell carcinoma (RCC) following two or more prior systemic therapies.

Cerecin appoints Dr. Marc Cantillon as Chief Medical Officer

Retrieved on: 
Monday, October 10, 2022
Merck, Therapy, VP, Food and Drug Administration Amendments Act of 2007, Cornell University, University, Kyowa Hakko Kirin, Peripheral nervous system, CEO, Geriatrics, Translation, Psychiatry, Wharton School of the University of Pennsylvania, Karolinska Institute, Athena, Drug development, Wilmar International, Lists of diseases, Investment, Internal medicine, Company, IP, GLOBE, CMO, Critical Path Institute, Schering, University of Pennsylvania, AstraZeneca, Risk, PD, Growth, Business administration, Research, Icahn School of Medicine at Mount Sinai, Neurology, CNS, AD, Neurodegeneration, Coalition, Central nervous system, Migraine, Genomics, Patient, Kyōwa, Partnership, North American Medical Management, Food, MD, Forward-looking statement, Insomnia, Mount Sinai, Pharmaceutical industry, Medicine, Pfizer, Sanofi

Cerecin expands senior management team with appointment of Dr. Marc Cantillon as Chief Medical Officer

Key Points: 
  • Cerecin expands senior management team with appointment of Dr. Marc Cantillon as Chief Medical Officer
    Dr. Cantillon brings over 25 years experience in senior Central Nervous System (CNS) development roles at Merck, Pfizer, Kyowa and Reviva Pharmaceuticals
    SINGAPORE and DENVER, Oct. 10, 2022 (GLOBE NEWSWIRE) -- Cerecin, Inc. a clinical-stage biotechnology company pioneering innovative neurotherapeutics, today announced the appointment of Marc Cantillon, MD, as Chief Medical Officer (CMO) of the Company.
  • Prior to this, Dr. Cantillon was Chief Medical Officer of Green Valley Pharmaceuticals, a biopharmaceutical company developing carbohydrate drugs in Parkinsonss Disease (PD) and Alzheimers Disease (AD).
  • Commenting on the appointment, Charles Stacey, CEO of Cerecin, said, We are very pleased to welcome Marc to our executive team.
  • Dr. Marc Cantillon, CMO of Cerecin, said, Cerecins metabolic approach to neurodegenerative disease has the potential to deliver novel treatment options to patients across several disease areas.